Phase I Study to Determine the Maximal Tolerated Dose and Dose-Limiting Toxicities of Orally Administered Idarubicin in Dogs with Lymphoma

Keyphrases

• Maximum Tolerated Dose 100%
• Dose-limiting Toxicity 100%
• Lymphoma 100%
• Phase I Study 100%
• Orally Administered 100%
• Idarubicin 100%
• Plasma Concentration 28%
• Antitumor Efficacy 28%
• Dose Escalation 14%
• Lymph Node 14%
• Owned Dogs 14%
• Hematologic 14%
• Antitumor Activity 14%
• Repeated Dose 14%
• Anthracyclines 14%
• Thrombocytopenia 14%
• Randomized Clinical Trial 14%
• Clinical Benefit 14%
• Neutropenia 14%
• Clinical Significance 14%
• Single Oral Dose 14%
• Bioavailable 14%
• Pharmacokinetic Parameters 14%
• Cohort Design 14%
• Skin Lesions 14%
• Anthracycline Antibiotics 14%
• Modified RECIST 14%
• Antibiotic Class 14%
• Alternative Supports 14%
• Similarity Classes 14%
• Number of Patients 14%
• Dose Level 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Idarubicin 100%
• Maximum Tolerated Dose 100%
• Idarubicinol 28%
• Antitumor Activity 14%
• Randomized Clinical Trial 14%
• Pharmacokinetic Parameter 14%
• Skin Defect 14%
• Anthracycline Antibiotic Agent 14%
• Thrombocytopenia 14%
• Neutropenia 14%
• Anthracycline 14%